As of November 14, 2026, Apellis Pharmaceuticals, Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from March 2, 2026 to May 14, 2026 (Form 8-K, May 14, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Apellis Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-05-14
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-03-31
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-03-02
Apellis Pharmaceuticals, Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-03-02 to 2026-05-14. Every row below is cited to the filing it comes from, and this page adds each new change as Apellis Pharmaceuticals, Inc. files it.
Also on the record for Apellis Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| June 5, 2026 | Stake report, Schedule 13G/A, by Morgan Stanley | — | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | 3.55% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by RTW Investments, LP | 2.9% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13D/A, by Biogen Inc. | — | 5%+ stakes | Source |
| May 12, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.4% of the class | 5%+ stakes | Source |
| April 7, 2026 | Stake report, Schedule 13G/A, by Wellington Management Group LLP | 0.2% of the class | 5%+ stakes | Source |
| April 6, 2026 | Stake report, Schedule 13D, by BIOGEN INC. | 14.2% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by RTW Investments, LP | 6.1% of the class | 5%+ stakes | Source |
| February 6, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 10.5% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by EcoR1 Capital, LLC | 2.7% of the class | 5%+ stakes | Source |
| November 7, 2025 | Stake report, Schedule 13G/A, by Wellington Management Group LLP | 10.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Apellis Pharmaceuticals, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Apellis Pharmaceuticals, Inc. and the records around it.
Apellis Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Jun 2026
Companies that share a holder
- Biogen Inc. also filed stake reports on 1 other company: Sage Therapeutics, Inc. (Jul 2025)
- EcoR1 Capital, LLC also filed stake reports on 20 other companies: Mereo BioPharma Group plc (Aug 2026), Alto Neuroscience, Inc. (Jul 2026), Fulcrum Therapeutics, Inc. (Jun 2026)
- RTW Investments, LP also filed stake reports on 43 other companies: ORCHESTRA BIOMED HOLDINGS, INC. (Nov 2026), CG Oncology, Inc. (Aug 2026), iRhythm Holdings, Inc. (Aug 2026)
Watch Apellis Pharmaceuticals, Inc.
Get an email when Apellis Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Apellis Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Apellis Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Apellis Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 13 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-14 | Reported | not named in the filing | 8-K, 2026-05-14 | ||
| 2026-03-31 | Reported | not named in the filing | 8-K, 2026-03-31 | ||
| 2026-03-02 | Reported | not named in the filing | 8-K, 2026-03-02 |
New leaders reset buying decisions — get the Full Report on Apellis Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Apellis Pharmaceuticals, Inc., with the record behind each one.
Find candidates like senior executive at Apellis Pharmaceuticals, Inc.Every change, in the filing's words
Reported
Effective as of the Effective Time, Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O'Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof.
- These resignations were tendered as a result of the Merger and were not a result of any disagreement between the Company and the directors on any matter relating to the Company's operations, policies or practices.
- In accordance with the terms of the Merger Agreement, effective as of the Effective Time, the director of Purchaser as of immediately prior to the Effective Time, Michael Dambach, became the director of the Company.
Reported
The Plan will automatically become effective upon, and subject to the occurrence of, the Merger and therefore will automatically terminate if the Merger Agreement is terminated without the consummation of the Merger.
- On March 30, 2026, the compensation committee of the Company Board approved the Apellis Pharmaceuticals, Inc. Excise Tax Gross-Up Plan (the "Plan"), which provides that "disqualified individuals" of the Company within the meaning of Section 280G of the Internal Revenue Code (including the Company's named executive officers) may become participants under the Plan.
- Each participant will have a right under the Plan to receive a gross-up payment in the event that any payments or benefits provided to such participant in connection with the Merger become subject to the excise tax pursuant to Section 4999 of the Internal Revenue Code of 1986, as amended.
- The gross-up payment would generally place the participant in the same after-tax position that the participant would have been in if the excise tax did not apply to the participant, subject to an aggregate $25 million cap in total gross-up payments that may be made to all participants under the Plan.
- Notwithstanding the foregoing, to the extent a participant's payments or benefits exceed the participant's applicable Section 280G safe harbor amount by 10% or less, the participant will instead receive a reduction of payments and benefits to the extent necessary to cause the payments not to become subject to the excise tax.
Reported
Dr. Dolsten has not been appointed to serve on any committees of the Board.
- On February 27, 2026, the Board of Directors (the "Board") of Apellis Pharmaceuticals, Inc. (the "Company"), upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Mikael Dolsten, M.D., Ph.D., to the Board as a Class I director, effective as of March 1, 2026, to serve until the Annual Meeting of Stockholders to be held in 2027 or until his successor has been duly elected and qualified or until his earlier death, resignation or removal.
- The Board has determined that Dr. Dolsten is "independent" as contemplated by the Nasdaq Stock Market rules.
- Dr. Dolsten will be compensated in the same manner as the Company's other non-employee directors.
- Information concerning the current compensation of the Company's directors for their service on the Board and its committees is set forth in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission (the "SEC") on April 23, 2025.
- In the event of a change in control of the Company, the vesting schedule of the option and the RSUs will accelerate in full.
- Pursuant to the terms of this agreement, the Company may be required, among other things, to indemnify Dr. Dolsten for some expenses, including attorneys' fees, judgments, fines and settlement amounts incurred by him in any action or proceeding arising out of his service as a director of the Company.
Tools for this story
Each opens in a new tab, filled in for Apellis Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
